Opinion|Videos|October 6, 2023
Sampling Methods for Patients with Metastatic Breast Cancer
Author(s)Rebecca A. Shatsky, MD
An expert on breast cancer provides clinical insights on liquid and tissue biopsies for patients with metastatic disease.
Advertisement
Episodes in this series
Advertisement
Related to this article
Giredestrant plus everolimus reduced the risk of progression or death by 44% in the ITT population and 62% in ESR1-mutated disease in phase 3 evERA data published in NEJM.
Elinzanetant, already approved for menopause-related VMS, is being considered to address hot flashes associated with adjuvant breast cancer endocrine therapy.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Ubamatamab Shows Durable Responses in Low-Grade Serous Ovarian Cancer
2
What Stood Out at IMS 2026? Five Myeloma Experts Weigh In
3
Giredestrant Plus Everolimus Improves PFS in ER+ Advanced Breast Cancer
4
New Drug Application Filed for Savolitinib/Osimertinib in MET+ NSCLC
5